SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-009999
Filing Date
2023-03-27
Accepted
2023-03-27 16:13:49
Documents
13
Period of Report
2023-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctmx-20230327.htm   iXBRL 8-K 56780
2 EX-99.1 ctmx-ex99_1.htm EX-99 272513
  Complete submission text file 0000950170-23-009999.txt   463277

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctmx-20230327.xsd EX-101.SCH 2451
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctmx-20230327_pre.xml EX-101.PRE 9831
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctmx-20230327_lab.xml EX-101.LAB 13360
7 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20230327_htm.xml XML 4725
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 23764672
SIC: 2834 Pharmaceutical Preparations